Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 3/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776988 | 0.86 | SYK (0.74) | SYKIGF1RRIPK1 | |
| SCHEMBL1776508 | 0.84 | SYK (0.68) | SYKIGF1RRIPK1 | |
| SCHEMBL2318518 | 0.82 | POLB (0.49) | SYKCYP1A2CYP2D6CYP2C19KMT2A | |
| SCHEMBL1777627 | 0.81 | SYK (0.75) | SYKIGF1RRIPK1 | |
| SCHEMBL13157584 | 0.81 | SYK (0.72) | SYKIGF1RRIPK1 | |
| SCHEMBL1777522 | 0.80 | SYK (0.70) | SYKIGF1RRIPK1 | |
| SCHEMBL12606314 | 0.79 | SYK (0.53) | SYKKMT2AIGF1RRIPK1 | |
| SCHEMBL1778784 | 0.79 | SYK (0.71) | SYKIGF1RRIPK1 | |
| SCHEMBL1779125 | 0.79 | SYK (0.71) | SYKIGF1RRIPK1 | |
| SCHEMBL1777291 | 0.79 | SYK (0.86) | SYKIGF1RRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |